Clinical Trial

68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)

Study acronym: FAP-IT
Recruiting
View on ClinicalTrials.gov →
Summary
Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-02; most recent amendment 2025-12-15.
Status change: Not Yet Recruiting → Recruiting 2024-10-16
Trial Details
NCT Number NCT06349512
Lead Sponsor Institut Curie
Conditions Triple Negative Breast Cancer
Enrollment 60 participants
Start Date 2024-10-14
Primary Completion 2032-11-30 (estimated)
Study Completion 2032-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-22